XI'AN, CHINA--(Marketwire - Aug 1, 2011) - Skystar Bio-Pharmaceutical Company (NASDAQ: SKBI) ("Skystar" or the "Company"), a China-based manufacturer and distributor of veterinary medicines, vaccines, micro-organisms and feed additives, today announced the appointment of Mr. Bing Mei to become the Company's permanent chief financial officer, effective as of July 29, 2011.
Mr. Mei is a seasoned chief financial officer fluent in both English and Mandarin with over 20 years of diverse industry experience including technology services and industrial manufacturing businesses and a successful track record of CFO/Controller roles with a variety of publicly traded Fortune 500 companies, fast-growing middle-market multinationals and international joint ventures. Prior to his engagement with Skystar Mr. Mei was chief financial officer of Avineon, a multinational technology company specializing in providing IT solutions to Federal and commercial industry with subsidiaries and joint ventures in Asia, Europe and North America and over 1,500 technical professionals located across the globe.
Mr. Mei is well acquainted with US and China GAAP, IFRS, SEC reporting standards and tax regulations, as well as SOX 404 compliance and in-depth knowledge of industry best practices, U.S. capital market and multinational financial operations. Mr. Mei is a certified public accountant (CPA), certified management accountant (CMA), and certified valuation analyst (CVA). He is a graduate of Zhejiang University with highest honors, Bowie State University and has a MBA from Duke University's Fuqua School of Business, where he was named a Fuqua Scholar graduating at the top ten percent of his class.
Mr. Weibing Lu, Skystar's chairman and CEO, commented, "We are pleased to have Bing Mei join Skystar as chief financial officer. Mr. Mei's experience in accounting and the international markets will assist the Company's growth initiatives as well as reporting and accountability to shareholders. Regrettably, Skystar accepted Michael Lan's resignation, concurrent to Bing Mei's appointment. Michael's resignation was due to personal reasons and there are no disputes between himself and the Company. Subsequently, we would like to thank Michael for his diligence and expertise in assisting Skystar grow record revenues and net income during his time with Skystar. We wish Michael all the best in his future endeavors."
PharmaVeterinary
skystarbio-ph...